Our Team
Leadership
Thomas Kallstenius
CEO & Co-founder
Thomas Kallstenius brings deep expertise at the intersection of AI, healthtech, and clinical translation. With a background spanning technology leadership and a commitment to improving mental healthcare through innovation, Thomas founded NeuroPrism to bridge the gap between cutting-edge neuroscience and practical clinical tools.
Under his leadership, NeuroPrism has developed an AI-powered mental health assessment platform validated in Nature Scientific Reports, and is advancing non-invasive temporal interference neuromodulation toward clinical deployment for alcohol use disorder.
Collaborative Network
NeuroPrism works with leading European research institutions and university hospitals across multiple countries, bringing together expertise in:
Addiction Psychiatry
Clinical trial execution, patient phenotyping, and addiction neurobiology at leading European university hospitals.
Neuromodulation Engineering
TI device design, stimulation targeting, digital twin modeling, and home-use system engineering.
Preclinical Neuroscience
Mechanistic validation in animal models, cross-species biomarker development, and translational neuroimaging.
AI & Data Science
NLP-based mental health assessment, ensemble machine learning, predictive modeling, and FAIR data governance.
Regulatory Translation
CE-marking pathway development, risk management, cybersecurity-by-design, and health-economic evaluation.
Join our mission
We are always looking for talented collaborators in neuroscience, AI, and clinical research.